A national cancer database analysis of the clinicopathologic characteristics and outcomes of appendiceal malignant mesenchymal tumors

Emile, Sameh Hany; Horesh, Nir; Garoufalia, Zoe; Gefen, Rachel; Zhou, Peige; Strassmann, Victor; Wexner, Steven D.

doi:10.1016/j.ejso.2023.106990

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a lack of high-quality randomized controlled trial evidence to support any specific treatment strategies for appendiceal GISTs. Nevertheless, in most cases, appendectomy alone appears to yield favorable outcomes [ 33 , 51 ]. In malignant GISTs, CTH (i.e., imatinib mesylate) might be applicable, but research is still ongoing [ 32 ].…”

Section: Grading and Staging Of Atsmentioning

confidence: 99%

Current Status of Treatment among Patients with Appendiceal Tumors—Old Challenges and New Solutions?

Chawrylak,

Leśniewska,

Mielniczek

et al. 2024

Cancers

View full text Add to dashboard Cite

The 5th edition of the World Health Organization (WHO) classification of tumors of the digestive system distinguishes four categories of appendiceal tumors (ATs): serrated lesions and polyps, mucinous neoplasms, adenocarcinomas, and neuroendocrine neoplasms (NENs). The differential diagnosis of ATs can be challenging in medical practice, due to their rarity and lack of data from randomized controlled trials on a large, diverse group of patients. ATs are usually noted in specimens obtained during appendectomies due to clinical acute appendicitis. In the European population, most ATs (65%) occur over the age of 50 and among women (56.8%). According to histological type, 54.6% are neuroendocrine tumors (NETs); 26.8% cystic, mucinous, and serous neoplasms; and 18.6% adenocarcinoma not otherwise specified (NOS). On pathologic analysis, most AT findings are benign lesions or small NENs that do not require further therapeutic measures. The presence of appendiceal mucinous neoplasm (AMN) can lead to pseudomyxoma peritonei (PMP). While the multimodal treatment for abdominal malignancies has evolved over the past several decades, the clinical workup and treatment of ATs remain a challenge. Therefore, this review aims to describe the diagnostic possibilities, molecular-based diagnosis, staging, differences in the treatment process, and prognostic factors associated with ATs.

show abstract

Section: Grading and Staging Of Atsmentioning

confidence: 99%